Mechanistic investigation of the inhibition of Abeta42 assembly and neurotoxicity by Abeta42 C-terminal fragments.

Oligomeric forms of amyloid beta-protein (Abeta) are key neurotoxins in Alzheimer's disease (AD). Previously, we found that C-terminal fragments (CTFs) of Abeta42 interfered with assembly of full-length Abeta42 and inhibited Abeta42-induced toxicity. To decipher the mechanism(s) by which CTFs affect Abeta42 assembly and neurotoxicity, here, we investigated the interaction between Abeta42 and CTFs using photoinduced cross-linking and dynamic light scattering. The results demonstrate that distinct parameters control CTF inhibition of Abeta42 assembly and Abeta42-induced toxicity. Inhibition of Abeta42-induced toxicity was found to correlate with stabilization of oligomers with a hydrodynamic radius (R(H)) of 8-12 nm and attenuation of formation of oligomers with an R(H) of 20-60 nm. In contrast, inhibition of Abeta42 paranucleus formation correlated with CTF solubility and the degree to which CTFs formed amyloid fibrils themselves but did not correlate with inhibition of Abeta42-induced toxicity. Our findings provide important insight into the mechanisms by which different CTFs inhibit the toxic effect of Abeta42 and suggest that stabilization of nontoxic Abeta42 oligomers is a promising strategy for designing inhibitors of Abeta42 neurotoxicity.

[1]  D. Gordon,et al.  Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Aβ1–40 fibrillogenesis , 2008 .

[2]  G. Bitan,et al.  C-terminal peptides coassemble into Aβ42 oligomers and protect neurons against Aβ42-induced neurotoxicity , 2008, Proceedings of the National Academy of Sciences.

[3]  D. Ehrnhoefer,et al.  EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers , 2008, Nature Structural &Molecular Biology.

[4]  H. Stanley,et al.  Elucidating Amyloid β-Protein Folding and Assembly: A Multidisciplinary Approach , 2006 .

[5]  D. Teplow,et al.  On the nucleation of amyloid β‐protein monomer folding , 2005 .

[6]  S. M. Robinson,et al.  Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's Disease* , 2003, The Journal of Biological Chemistry.

[7]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[8]  L. Kiessling,et al.  Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. , 2001, Biochemistry.

[9]  A. Doig,et al.  Inhibition of Toxicity in the β-Amyloid Peptide Fragment β-(25–35) Using N-Methylated Derivatives , 2000, The Journal of Biological Chemistry.

[10]  P. Fraser,et al.  Inositol Stereoisomers Stabilize an Oligomeric Aggregate of Alzheimer Amyloid β Peptide and Inhibit Aβ-induced Toxicity* , 2000, The Journal of Biological Chemistry.

[11]  T. Kodadek,et al.  Chemistry for the analysis of protein-protein interactions: rapid and efficient cross-linking triggered by long wavelength light. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Soto,et al.  Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. , 1996, Biochemical and biophysical research communications.

[13]  L. Tjernberg,et al.  Arrest of -Amyloid Fibril Formation by a Pentapeptide Ligand (*) , 1996, The Journal of Biological Chemistry.

[14]  S. Sahasrabudhe,et al.  Two-hybrid system as a model to study the interaction of beta-amyloid peptide monomers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Kirschner,et al.  On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M J Ball,et al.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. May,et al.  β-amyloid peptide in vitro toxicity: Lot-to-lot variability , 1992, Neurobiology of Aging.

[18]  R. B. Merrifield.  Automated synthesis of peptides. , 1965, Science.

[19]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[20]  Chun Wu,et al.  The structure of A β 42 C-terminal fragments probed by a combined experimental and theoretical study , 2009 .

[21]  G. Bitan,et al.  Synthesis and Purification of Highly Hydrophobic Peptides Derived from the C-Terminus of Amyloid β-Protein. , 2008, The open biotechnology journal.

[22]  S. Ferreira,et al.  Soluble protein oligomers as emerging toxins in alzheimer's and other amyloid diseases , 2007, IUBMB life.

[23]  K. Sciarretta,et al.  Peptide-based inhibitors of amyloid assembly. , 2006, Methods in enzymology.

[24]  G. Bitan.  Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins. , 2006, Methods in enzymology.

[25]  Yun-Ru Chen,et al.  DISTINCT EARLY FOLDING AND AGGREGATION PROPERTIES OF ALZHEIMER AMYLOID-ß PEPTIDE Aß40 AND Aß42: STABLE TRIMER OR TETRAMER FORMATION BY Aß42. , 2006 .

[26]  G. Bitan,et al.  Preparation of aggregate-free, low molecular weight amyloid-beta for assembly and toxicity assays. , 2005, Methods in molecular biology.

[27]  M. Kirkitadze,et al.  Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Kiessling,et al.  Recognition Sequence Design for Peptidyl Modulators of ‚-Amyloid Aggregation , 1999 .

[29]  D. Kirschner,et al.  Nucleation and Growth of Amyloid β-Protein Fibrils: Detection of Nuclei and Quantitation of Rate Constants , 1996, Photon Correlation & Scattering.